Romosozumab Treatment in Postmenopausal Women with Osteoporosis - Test2 - elhamkhani - TriplyDB

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

http://www.wikidata.org/entity/Q28278665

about

Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting Imminent fracture risk.Profile of romosozumab and its potential in the management of osteoporosis.Recent advances in the management of osteoporosis Romosozumab for the treatment of osteoporosis.Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys.Antibodies to watch in 2017 Osteoporosis Therapy: Bone Modeling during Growth and Aging.Advances in treatment of glucocorticoid-induced osteoporosis.Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments.New anabolic therapies for osteoporosis.Regulation of Bone Metabolism by Sex Steroids.The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.Review: Breaking From Bisphosphonates.WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer.The quest for new drugs to prevent osteoporosis-related fractures.Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.Positioning novel biologicals in CKD-mineral and bone disorders.Connecting Bone and Fat: The Potential Role for Sclerostin.Bone-seeking agents for the treatment of bone disorders.Using Osteoporosis Therapies in Combination.Osteoporosis treatment: recent developments and ongoing challenges.Wnt signaling in cardiovascular disease: opportunities and challenges.Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.WNT-activated bone grafts repair osteonecrotic lesions in aged animals.Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs.Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes.Increased Ca2+ signaling through CaV1.2 promotes bone formation and prevents estrogen deficiency-induced bone loss.Levels of serum sclerostin, metabolic parameters, and periodontitis in -postmenopausal women with diabetes.MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.Monoclonal antibodies for treating osteoporosis.Normative values for CT-based texture analysis of vertebral bodies in dual X-ray absorptiometry-confirmed, normally mineralized subjects.Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems.Osteoblast as a target of anti-osteoporotic treatment.Emerging anabolic agents in the treatment of osteoporosis.Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment.Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys.

P2860

Q30234621-2AF7BF00-E12F-464B-A34A-0F44BF0D1E99 Q30235569-47873909-E71E-4906-AF9A-443D27A909C5 Q33596475-B68A3C38-3454-435A-AAFA-A49E2D606ED8 Q33672136-03816A89-5EC5-43EC-9D64-D97BA3BDF862 Q34680463-AFD0EC5D-1713-4503-8FA8-5D25E4B00C24 Q36198506-8052F87B-E0EB-4DB2-95C5-260B3F473C78 Q37631319-49A2527E-E42B-4849-B54F-FC28E7330917 Q37689421-D7FEFC48-D64D-45A9-919B-624F95F01CB7 Q38600333-96D162F4-DEC4-48C7-BCF9-E1DFA1FAA8B7 Q38610545-B78F4EF4-6E4A-46E9-AB3D-71C6C85F0621 Q38646406-354DE3AA-02BA-46AD-9683-98B7AB9767E4 Q38657323-F98CB377-4A49-4AB2-ADC9-EB6E8A25D22C Q38687054-5FC4543A-D956-4EC6-950D-311B9350844D Q38749233-B46989C1-3F17-4EE6-9CC3-673787E16311 Q38992765-00629366-74B1-4CCD-B98B-9AF200786561 Q39154095-73BC2998-36E8-4417-B0DA-71ED268F271F Q39175749-19EDC3C7-CF82-4E3D-8616-3A2C163C6593 Q39255870-9723DAC6-36E6-45A9-B2F1-C9070A95536C Q39328170-C780B225-0D58-4701-AA1B-916281920642 Q39350147-A26F5A19-6923-4A3E-BE78-353BEFB904A3 Q39356298-BC24AD0E-F5C8-4056-A3F0-F02C9B9ADD7F Q39408210-26661878-6841-4A03-8D84-0421B42036F0 Q39423904-901F30F2-C4CC-453D-815C-B73FC46BC1A8 Q39445406-C9736C6A-D3EA-4240-8D59-25A9364BCFAE Q40437923-5A067A22-B250-48DF-A1C7-2E4D503767C2 Q42364116-214125E6-2DEB-4674-98B3-D4B2C9B969CA Q44385408-17036AD8-96E9-4796-AFC5-47305EBFC6F4 Q47136618-39266C04-EFE8-4FC1-9789-2B5955715B1E Q47327411-8503E3F3-4DFE-4CF9-9E72-DCA0166DF1F4 Q47373022-F1103E05-3D06-4142-8BAF-285118E5AAE1 Q47384432-68F05BF5-B0F9-42D5-8160-950CB93C8F60 Q47428797-CD421B23-BDF3-4262-8B02-5D40C21C01D7 Q47638169-A2277A61-CA72-43DD-B42A-C6AEF2C515C0 Q47675387-09B58D8B-33DC-4A55-ADB0-FE4A6A90F96E Q47944184-76360A38-7BB2-4AAB-A30A-A8C540B7AF3B Q47996918-8F3B27FC-9383-4C21-A646-DD5D6942181E Q48012226-1124D5F6-554F-45B9-8998-179538016FED Q48088703-230D94B7-D104-4C6E-97E7-3E7D470FFB1D Q48166426-1751FB65-A972-433D-B494-C2DEE32392CF Q48182585-E26117C3-C690-4DCD-9F86-02D096785703

P2860

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

http://www.wikidata.org/entity/Q28278665

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@ast

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@en

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@nl

type

label

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@ast

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@en

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@nl

prefLabel

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@ast

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@en

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@nl

P1433

Q28278665-42DE1D76-C060-4634-ADFE-489E060D4E1F

P1476

Q28278665-F8B111DC-1908-43CB-9050-FAFD3C2BD149

P2093

Q28278665-1DBC02A4-0DF8-4964-9FB0-3EF52482FD03

Q28278665-29D958F8-DFD7-44B7-88C1-0F8BC757657B

Q28278665-3CC88398-4101-4B25-80DC-F0BA32626F06

Q28278665-49942737-EC99-4AD0-9C22-EAA4732D066F

Q28278665-84611A33-32AA-48E9-A95F-80CB51046C64

Q28278665-89981410-5E30-4BC3-8D0F-62A1C98C3A8E

Q28278665-9D6DB259-299A-4508-B0BC-C033152896C2

Q28278665-A0526AEA-7B37-4EEB-90DF-1A6DA1EE3B02

Q28278665-A562F8F0-EDA5-4368-BC1B-2A89B5C09C8F

Q28278665-B4A20C83-07B1-4758-A936-6D66EA034775

P304

Q28278665-009A8EF2-D792-4E1F-9749-4EAD8CE2AB76

P31

Q28278665-D34A05C7-B412-46A3-886C-ABA6BC5AE368

P356

Q28278665-4859561B-D673-4EF1-9B0E-A84DEDC254BA

P407

Q28278665-5A3E18F6-8D8C-43A1-B9B7-336656402E4F

P433

Q28278665-7806F657-EBC5-4880-A6CF-CE7069B09D19

P478

Q28278665-A3D3EB3A-5C34-4F76-9C91-88FBD83BD677

P50

Q28278665-82C5BC05-759F-4D10-90E2-C9F81DC5E9D9

P577

Q28278665-4BF1555E-DD8E-4092-8472-AA8EF31459B6

P698

Q28278665-EE714F9F-EDFD-4EBD-BFD8-D72E990EC6C9

P921

Q28278665-1AAE48FA-9FFE-4107-B7E3-86DBDE96082A

P356

P1433

The New England Journal of Medicine

P1476

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

@en

P2093

Akimitsu Miyauchi

http://www.w3.org/2001/XMLSchema#string

Andreas Grauer

http://www.w3.org/2001/XMLSchema#string

Cassandra E Milmont

http://www.w3.org/2001/XMLSchema#string

Cesar Libanati

http://www.w3.org/2001/XMLSchema#string

Cristiano A F Zerbini

http://www.w3.org/2001/XMLSchema#string

Daria B Crittenden

http://www.w3.org/2001/XMLSchema#string

E Michael Lewiecki

http://www.w3.org/2001/XMLSchema#string

Edith Lau

http://www.w3.org/2001/XMLSchema#string

Edward Czerwinski

http://www.w3.org/2001/XMLSchema#string

Felicia Cosman

http://www.w3.org/2001/XMLSchema#string

P304

1532-1543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1607948

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Lorenz C Hofbauer

P577

2016-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27641143

http://www.w3.org/2001/XMLSchema#string

P921